Strand Therapeutics
Focus: Strand Therapeutics is a Boston-based gene therapy biotech founded in 2018, focused on developing innovative therapeutic approaches for serious diseases. The company is at Series B stage with a small but growing team.
Profile data last refreshed 1m ago · AI intelligence enriched 2w ago
Funding Stage
SERIES B
Open Jobs
7-3 this month
Stable — net -3 jobs in 30d
0 added, 3 removed. Backfill posture.
Should You Work at Strand Therapeutics?
AI assessmentBest fit for scientists and translational professionals seeking early-stage gene therapy exposure and meaningful ownership; higher risk for those prioritizing job security.
Why Work Here
- Early-stage gene therapy platform with active clinical programs (3 trials including Phase 1/2 STX-001 in solid tumors) offering exposure to cutting-edge science
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Bubble CPAP- BabiPlus, Respiralogics
Respiratory Distress SyndromeClinical Trials (1)
NCT02392806Comparative Effectiveness Study of Bubble CPAP Devices in the NICU
N/AHelp build intelligence for Strand Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.